The Swedish MS registry – clinical support tool and scientific resource

Abstract

The Swedish MS registry (SMSreg) is designed to assure quality health care for patients with multiple sclerosis (MS). It has been active since 2001 and web-based since 2004. It runs on government funding only and is used in all Swedish neurology departments. The SMSreg currently includes data on 14,500 of Sweden's estimated 17,500 prevalent patients with MS. One important function of SMSreg, to which participation is voluntary, is to serve as a tool for decision support and to provide an easy overview of the patient information needed at clinical visits. This is its core feature and explains why the majority of Swedish MS specialists contribute data. Another success factor for SMSreg is that entered data can be readily accessed, either through a query function into Excel format or through a set of predesigned tables and diagrams in which parameters can be selected. Recent development includes a portal allowing patients to view a summary of their registered data and to report a set of patient-reported outcomes. SMSreg data have been used in close to 100 published scientific reports. Current projects include an incidence cohort (EIMS), post-marketing cohorts of patients on novel disease-modifying drugs (IMSE), and a prevalence cohort (GEMS). As these studies combine physical sampling and questionnaire data with clinical documentation and possible linkage to other public registries, together they provide an excellent platform for integrated MS research.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 29

1. 1.

   Andersen O. From the Gothenburg cohort to the Swedish multiple sclerosis registry. Acta Neurol Scand. 2012;195:13-9.

   Not in our library10.1111/ane.12023

2. 2.

   Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116(Pt 1):117-34.

   Not in our library10.1093/brain/116.1.117

3. 3.

   Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry. 2002;73:701-4.

   Not in our library10.1136/jnnp.73.6.701

4. 4.
   Comparison of the SF6D, the EQ5D, and the oswestry disability index in patients with chronic low back pain and degenerative disc disease · 2013

   No notice
5. 5.

   Stawiarz L, Hagel E, Eriksson H, Hillert J, Swedish MS Registry. A visualization and analysis platform in the Swedish national MS registry for real-time data feedback. Mult Scler. 2014;20(Suppl 1):163-4.

   Not in our library

6. 6.

   Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler. 2013;19:765-74.

   Not in our library10.1177/1352458512463764

7. 7.

   Westerlind H, Ramanujam R, Uvehag D, et al. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain. 2014;137:770-8.

   Not in our library10.1093/brain/awt356

8. 8.

   Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-9.

   Not in our library10.1038/nature10251

9. 9.

   Beecham AH, Patsopoulos NA, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353-60.

   Not in our library10.1038/ng.2770

10. 10.

    Piehl F, Holmen C, Hillert J, Olsson T. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci. 2011;31(Suppl. 3):289-93.

    Not in our library10.1007/s10072-010-0345-y

11. 11.

    Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology. 2009;73:696-701.

    Not in our library10.1212/wnl.0b013e3181b59c40

12. 12.

    Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult Scler. 2011;17:788-93.

    Not in our library10.1177/1352458511399610

13. 13.

    Baarnhielm M, Hedstrom AK, Kockum I, et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur J Neurol. 2012;19:955-62.

    Not in our library10.1111/j.1468-1331.2011.03650.x

14. 14.

    Hedstrom AK, Hillert J, Olsson T, Alfredsson L. Nicotine might have a protective effect in the etiology of multiple sclerosis. Mult Scler. 2013;19:1009-13.

    Not in our library10.1177/1352458512471879

15. 15.

    Sundqvist E, Sundstrom P, Linden M, et al. Epstein–Barr virus and multiple sclerosis: interaction with HLA. Genes Immun. 2012;13:14-20.

    Not in our library10.1038/gene.2011.42

16. 16.

    Hedstrom A, Alfredsson L, Lundkvist Ryner M, Fogdell-Hahn A, Hillert J, Olsson T. Smokers run increased risk of developing anti-natalizumab antibodies. Mult Scler. 2013;20:1081-5.

    Not in our library10.1177/1352458513515086

17. 17.
    Smoking and multiple sclerosis susceptibility · 2013

    No notice
18. 18.

    Hedstrom AK, Hillert J, Olsson T, Alfredsson L. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol. 2014;71:300-5.

    Not in our library10.1001/jamaneurol.2013.5858

19. 19.

    Hedstrom AK, Hillert J, Olsson T, Alfredsson L. Reverse causality behind the association between reproductive history and MS. Mult Scler. 2014;20:406-11.

    Not in our library10.1177/1352458513498126

20. 20.

    Baarnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Mult Scler. 2014;20:726-32.

    Not in our library10.1177/1352458513509508

21. 21.

    Hedstrom AK, Sundqvist E, Baarnhielm M, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain. 2011;134:653-64.

    Not in our library10.1093/brain/awq371

22. 22.

    Link J, Lundkvist Ryner M, Fink K, et al. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. PLoS ONE. 2014;9:e90479.

    Not in our library10.1371/journal.pone.0090479

23. 23.

    Hedstrom AK, Ryner M, Fink K, et al. Smoking and risk of treatment-induced neutralizing antibodies to interferon beta-1a. Mult Scler. 2014;20:445-50.

    Not in our library10.1177/1352458513498635

24. 24.

    Imrell K, Landtblom AM, Hillert J, Masterman T. Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology. 2006;67:1062-4.

    Not in our library10.1212/01.wnl.0000237343.93389.35

25. 25.
    Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. · 2013

    Not checked
26. 26.

    Gustavsen MW, Viken MK, Celius EG, et al. Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. J Neuroimmunol. 2014;274:174-9.

    Not in our library10.1016/j.jneuroim.2014.06.024

27. 27.

    Karrenbauer VD, Prejs R, Masterman T, Hillert J, Glaser A, Imrell K. Impact of cerebrospinal-fluid oligoclonal immunoglobulin bands and HLA-DRB1 risk alleles on brain magnetic-resonance-imaging lesion load in Swedish multiple sclerosis patients. J Neuroimmunol. 2013;254:170-3.

    Not in our library10.1016/j.jneuroim.2012.08.011

28. 28.

    Ferreira D, Voevodskaya O, Imrell K, et al. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy. J Neuroimmunol. 2014;274:149-54.

    Not in our library10.1016/j.jneuroim.2014.06.010

29. 29.

    Ahlgren C, Oden A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler. 2011;17:901-8.

    Not in our library10.1177/1352458511403794

Cited by papers we hold 2

• Epidemiology of multiple sclerosis in Central Europe, update from Hungary · 2020
  Not checked
• Model-Driven Decision Making in Multiple Sclerosis Research: Existing Works and Latest Trends · 2020
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.